Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors

摘要

Abstract In donor selection for allogeneic stem cell transplant, several factors are considered for potential impact on transplant outcome. Previous publications suggested single HLA‐mismatched unrelated donors (MMUD) may be equivalent to 10/10 matched unrelated donors (MUDs). We retrospectively examined factors affecting outcome in a single‐center study using ATG followed by post‐transplant cyclophosphamide, termed ATG‐PTCy, GvHD prophylaxis. Fifty‐two patients who received grafts from MMUD and 188 patients transplanted from MUD between January 2015 and December 2019, at Princess Margaret Cancer Centre, Canada, were enrolled. All patients received reduced‐intensity conditioning. Overall survival for 9/10 recipients at 2?years was significantly worse, 37.2% versus 68.5% for 10/10 MUDs, p?